Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 03 - 03 tags : Disease save search
First Wave BioPharma Announces Poster Presentation at the 2022 Digestive Disease Week (DDW) Conference
Published: 2022-03-03 (Crawled : 00:00) - biospace.com/
FWBI | $2.84 -2.07% -2.84% 30K
|
Manufacturing
|
| O: -3.42%
H: 0.0%
C: 0.0%
biopharma conference presentation disease
Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Programs for the Treatment of Guillain-Barré Syndrome and Huntington’s Disease at AAN 2022
Published: 2022-03-03 (Crawled : 22:00) - biospace.com/
ANNX | $4.44 -3.16% -3.38% 1.3M
|
Health Technology
|
| O: 1.3%
H: 0.0%
C: -6.21%
huntington treatment program disease preclinical bioscience syndros pre-clinical huntington’s disease
Better Therapeutics Sponsors Educational Symposium on the Use of Software as a Next-Generation Treatment for Cardiometabolic Diseases
Published: 2022-03-03 (Crawled : 17:00) - biospace.com/
BTTX | $0.009 -3.23% -65.02% 260K
|
|
| O: 0.0%
H: 3.46%
C: -3.08%
treatment symposium metabolic cardio therapeutics disease education software pons
Palatin Hosting Key Opinion Leader Webinar on Dry Eye Disease
Published: 2022-03-03 (Crawled : 13:00) - palatin.com
PTN | $1.89 -0.53% 0.0% 180K
|
Health Technology
|
| O: 0.27%
H: 0.92%
C: -3.15%
dry eye eye eye disease disease
Global Therapeutic Drug Monitoring (TDM) Markets, 2022-2030 - Opportunities in the Increasing Adoption in the Treatment of Autoimmune Diseases
Published: 2022-03-03 (Crawled : 12:30) - prnewswire.com
TMO | News | $541.52 -1.05% -0.1% 1.8M
|
Health Technology
|
| O: 3.09%
H: 0.0%
C: 0.0%
DHR | $236.36 -1.27% 0.24% 4.3M
|
Health Technology
|
| O: 1.61%
H: 0.0%
C: 0.0%
XGN | $1.4289 2.06% -4.0% 8.5K
|
Health Services
|
| O: 3.91%
H: 4.02%
C: -3.9%
treatment drug disease
Cell Therapy Market 2022-2026 | Increasing Prevalence of Chronic Diseases to Boost Growth | Technavio
Published: 2022-03-03 (Crawled : 11:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -3.02%
H: 0.0%
C: -0.06%
ALPMY | $9.47 0.11% -1.11% 520K
|
Manufacturing
|
| O: -1.78%
H: 1.63%
C: 1.5%
NVS | $92.57 -0.55% 0.27% 840K
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
BCLI | $0.5143 -4.9% -7.51% 1.1M
|
Health Technology
|
| O: -0.64%
H: 2.09%
C: -2.25%
disease cel therapy growth
Nirsevimab significantly protected infants against RSV disease in Phase 3 trial
Published: 2022-03-03 (Crawled : 09:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -6.92%
H: 1.86%
C: 1.86%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
trial disease phase 3
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.